Researchers have found that treatment with very low doses of a dopamine-1 receptor (D1R) agonist was not effective in reducing the cognitive and negative symptoms of schizophrenia.
Columbia neuroscientists have described the activity of newly generated brain cells in awake mice—a process known as adult neurogenesis—and revealed the critical role these cells play in forming memories.
